Experimental HCV Drugs
Experimental HCV Drugs
Achillion Finds Promising New HCV NS5A Inhibitor Candidate
- Details
- Category: HCV Treatment
- Published on Tuesday, 01 November 2011 00:00
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals recently announced that it has selected a second-generation hepatitis C virus (HCV) NS5A inhibitor for development, designated ACH-3102. NS5A inhibitors are among the direct-acting antiviral agents that have begun to revolutionize hepatitis C treatment. The function of the HCV NS5A protein is not fully understood, but it appears to both play a role in viral replication and influence host response.
Vertex to Test 12-Week Telaprevir for People with Favorable IL28B Gene Pattern
- Details
- Category: HCV Treatment
- Published on Friday, 28 October 2011 00:00
- Written by Vertex Pharmaceuticals
Vertex Pharmaceuticals this week announced the initiation of a new Phase 3b clinical trial (CONCISE) to test whether the recently approved hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) plus pegylated interferon/ribavirin can cure treatment-naive patients and prior relapsers with the favorable IL28B CC gene pattern in just 12 weeks.
Telaprevir (Incivo) for Chronic Hepatitis C Approved in Europe
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 30 September 2011 00:00
- Written by Janssen
The European Commission last week approved the hepatitis C virus (HCV) protease inhibitor telaprevir for treatment of genotype 1 chronic hepatitis C in both previously untreated people and prior non-responders to interferon-based therapy.
HCV Polymerase Inhibitor Setrobuvir Looks Safe and Effective in Interim Analysis
- Details
- Category: HCV Treatment
- Published on Tuesday, 25 October 2011 00:00
- Written by Anadys
The investigational hepatitis C virus (HCV) polymerase inhibitor setrobuvir (ANA598) has demonstrated good efficacy to date in an ongoing Phase 2b trial, producing viral suppression in more than three-quarters of prior non-responders and relapsers. About 70% of treatment-naive patients were eligible for short-duration treatment based on early virological response.
Pharmasset Starts Trial of PSI-7977 and PSI-938 Oral Regimens for All HCV Genotypes
- Details
- Category: HCV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Pharmasset
Pharmasset last week announced the initiation of a new Phase 2b clinical trial that will test the company's investigational nucleotide HCV polymerase inhibitors, PSI-7977 and PSI-938, in various interferon-sparing oral regimens with or without ribavirin.
Web Design and Development by